Your browser is no longer supported. Please, upgrade your browser.
JAZZ Jazz Pharmaceuticals Public Limited Company daily Stock Chart
Jazz Pharmaceuticals Public Limited Company
Index- P/E28.53 EPS (ttm)5.29 Insider Own2.70% Shs Outstand61.16M Perf Week6.35%
Market Cap9.23B Forward P/E11.73 EPS next Y12.87 Insider Trans-4.00% Shs Float59.04M Perf Month7.42%
Income333.00M PEG1.56 EPS next Q2.80 Inst Own93.60% Short Float2.17% Perf Quarter0.18%
Sales1.35B P/S6.83 EPS this Y460.60% Inst Trans0.30% Short Ratio1.50 Perf Half Y17.27%
Book/sh26.29 P/B5.74 EPS next Y15.45% ROA9.70% Target Price187.07 Perf Year-20.70%
Cash/sh16.03 P/C9.42 EPS next 5Y18.27% ROE21.40% 52W Range108.50 - 194.73 Perf YTD7.41%
Dividend- P/FCF16.90 EPS past 5Y44.40% ROI13.80% 52W High-22.47% Beta0.79
Dividend %- Quick Ratio3.10 Sales past 5Y50.10% Gross Margin92.80% 52W Low39.14% ATR4.56
Employees920 Current Ratio3.20 Sales Q/Q8.60% Oper. Margin36.70% RSI (14)61.14 Volatility4.32% 2.75%
OptionableYes Debt/Eq0.74 EPS Q/Q5.70% Profit Margin24.60% Rel Volume1.51 Prev Close152.82
ShortableYes LT Debt/Eq0.71 EarningsAug 03 AMC Payout0.00% Avg Volume853.94K Price150.97
Recom1.80 SMA206.49% SMA503.62% SMA2009.69% Volume1,288,632 Change-1.21%
Jul-19-16Reiterated Mizuho Buy $193 → $195
Jun-06-16Initiated Goldman Buy $196
May-11-16Upgrade Mizuho Neutral → Buy $137 → $193
May-11-16Reiterated UBS Buy $162 → $168
Apr-25-16Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Feb-24-16Reiterated Mizuho Neutral $140 → $124
Feb-19-16Initiated Wells Fargo Outperform
Nov-25-15Initiated Bernstein Mkt Perform
Nov-10-15Downgrade Mizuho Buy → Neutral $164 → $140
Oct-14-15Initiated Northland Capital Outperform $200
Oct-09-15Initiated Mizuho Buy
Jun-29-15Reiterated UBS Buy $190 → $210
May-26-15Reiterated Guggenheim Buy $210 → $220
Feb-25-15Reiterated Deutsche Bank Buy $176 → $185
Feb-20-15Initiated BMO Capital Markets Outperform $200
Nov-05-14Upgrade R. F. Lafferty Neutral → Buy $200
May-09-14Reiterated R. F. Lafferty Neutral $140 → $130
Apr-17-14Initiated Canaccord Genuity Buy $163
Mar-07-14Resumed Barclays Overweight $200
Feb-26-14Reiterated Stifel Buy $145 → $195
Jul-29-16 03:27PM  Jazz Financing I Ltd. -- Moody's: Xyrem Patent Loss Is Credit Negative, but Other Patents Still Exist; Ratings Unaffected at Moody's
08:05AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : July 29, 2016
Jul-28-16 04:05PM  Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies PR Newswire +7.69%
06:18AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events
Jul-27-16 11:49AM  Actinium Pharmaceuticals: Another Promising Name In The AML Space
Jul-25-16 04:05PM  Jazz Pharmaceuticals to Report 2016 Second Quarter Financial Results on August 9, 2016 PR Newswire
Jul-22-16 12:05PM  What Is An Options Sweep?
Jul-18-16 01:03PM  This Could Be the Next Big Pharma Buyout at Motley Fool
Jul-17-16 01:59PM  Forget the Me-Too Cancer Drugs -- These Breakthroughs Are Where You Want to Invest at Motley Fool
Jul-15-16 09:17AM  Bulls Crowd Into Jazz Pharmaceuticals For Good Reason at Forbes
09:06AM  Jazz Pharmaceuticals: How Much Return Potential Does It Have?
Jul-14-16 01:11PM  Ligand Pharmaceuticalss Performance Based on EV-to-EBITDA
01:11PM  Understanding Ligand Pharmaceuticalss PE Multiple
11:08AM  A Look at Celators Lead Drug Vyxeos
10:06AM  How Can Celators Portfolio Complement Jazz Pharmaceuticals?
Jul-13-16 03:51PM  A Look at Jazz Pharmaceuticals Celator Acquisition Deal
03:51PM  Why Did Jazz Fall after Celator Acquisition Announcement?
01:16PM  Jazz Financing I Ltd. -- Moody's: Jazz's Upsized revolving credit facility is positive for liquidity; ratings unaffected at Moody's
Jul-12-16 04:04PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a Direct
01:50AM  Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc. PR Newswire
Jun-29-16 04:25PM  Jazz Pharma (JAZZ) Stock Receives 'Outperform' Rating at BMO Capital
Jun-27-16 08:21AM  Why Celator Pharmaceuticals Is Up 1,610% in 2016 at Motley Fool
12:09AM  Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition PR Newswire
Jun-23-16 06:55AM  Five companies that could buy Ariad this year for as much as $2.9B at
Jun-20-16 04:30PM  Jazz Pharmaceuticals PLC Conference Call to Discuss On JZP-110 Investor Update scheduled for 4:30 pm ET today
03:37PM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : June 20, 2016
Jun-15-16 09:42AM  Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
08:03AM  4 Cancer Drug Developers You Need to Have on Your Radar This Year at Motley Fool
Jun-14-16 04:05PM  Jazz Pharmaceuticals Announces Conference Call and Webcast for JZP-110 Investor Update PR Newswire
09:05AM  Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting PR Newswire
08:34AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : June 14, 2016
Jun-10-16 06:42PM  5 Appealing Biotechnology Stocks for Healthy Long-term Returns
Jun-06-16 04:43PM  Jazz Pharma Started At Buy; Visa And Wal-Mart Upgraded
10:14AM  Specialty Pharma: After the M&A Fueled Super Cycle at
10:01AM  3 Cheap Biotech Stocks You Can Buy Now at Motley Fool
07:29AM  Coverage initiated on Jazz Pharma by Goldman
Jun-04-16 09:40AM  Why Celator Pharmaceuticals Shares Skyrocketed 100% in May at Motley Fool
Jun-03-16 06:21PM  Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders PR Newswire
01:29PM  Sarepta Therapeutics: Bears are 'Fundamentally Wrong.' Here's Why. at
09:46AM  The market is looking for a Celator spoiler bid
Jun-02-16 09:03AM  3 Incredibly Cheap Biotech Stocks at Motley Fool
Jun-01-16 01:17PM  Yes, Biotech Unicorns Are Still Real at Bloomberg
11:15AM  8 Mergers You Might Have Missed On Tuesday
10:55AM  CPXX: Jazz Acquires Celator for $30.25 per Share
07:30AM  [$$] Venture Investors in Celator Pharma Rewarded for Taking the Long View at The Wall Street Journal
06:07AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits
May-31-16 05:20PM  Top Trades: Biotech bottom in?
04:36PM  Jazz Pharma Paying 4 Times Peak Sales For Celator Leukemia Drug
03:29PM  Stocks on Track for Mixed May as Dow Loses Gains
12:22PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Celator Pharmaceuticals, Inc. to Jazz Pharmaceuticals plc - CPXX Accesswire
12:14PM  Why Celator Pharmaceuticals, Cliffs Natural Resources and 3 Other Stocks are Flying High Today at Insider Monkey
11:30AM  Here's Why Shares of Celator Are Climbing on Tuesday at TheStreet
11:14AM  A bunch of hedge funds are cashing in big on the Celator drug deal
11:09AM  Stocks Waver as Boost in Spending Lifts Rate Hike Chances
11:06AM  Why Celator Pharmaceuticals Shares Are Skyrocketing Today at Motley Fool
10:32AM  Jazz Pharmaceuticals buying Celator for $1.5B at USA TODAY
10:29AM  Jazz Pharmaceuticals Agrees to Buy Celator for About $1.5 Billion at The Wall Street Journal
10:20AM  Micron Technology jumps on upgrade, Celator surges on Jazz buyout
09:25AM  Morning Movers: CPXX, VZ, VLKAY
08:42AM  Stock Futures Higher as Spending Sees Biggest Jump in Seven Years
08:41AM  Jazz Pharmaceuticals Strikes Celator Takeover Pact
08:19AM  Consumers spending posts biggest gain in nearly 7 years
08:01AM  Trending Now: JAZZ
07:30AM  Here's a super-quick guide to what traders are talking about right now
07:15AM  Jazz Pharmaceuticals to Buy Celator for about $1.5 bln at MarketWatch
06:55AM  10 things you need to know today
06:10AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Ot
04:05AM  Jazz Pharmaceuticals to Acquire Celator Pharmaceuticals for $30.25/Share in Cash
04:04AM  Jazz Pharma to buy Celator in $1.5 bln deal
03:49AM  Jazz Pharmaceuticals Agrees to Buy Celator for $1.5 Billion at Bloomberg
03:30AM  Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share PR Newswire
12:06AM  Jazz Pharmaceuticals Nears Deal to Buy Celator for About $1.5 Billion at The Wall Street Journal
May-30-16 11:59PM  Jazz Pharmaceuticals Nears Deal to Buy Celator for About $1.5 Billion at The Wall Street Journal
May-27-16 02:47PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Jazz Pharmaceuticals plc Business Wire
11:41AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jazz Pharmaceuticals plc - JAZZ PR Newswire
05:00AM  Gilead Subpoenaed as Feds Probe Drugmaker-Charity Connections at Bloomberg
May-26-16 10:03AM  Term Sheet Thursday, May 25 at Fortune
May-25-16 01:36PM  [$$] Drug Developer Arrivo BioVentures Launches With $49M at The Wall Street Journal
May-20-16 03:46PM  How Big Pharma Uses Charity Programs To Cover Drug Price Hikes
May-19-16 07:36PM  ETFs with exposure to Jazz Pharmaceuticals Plc : May 19, 2016
06:00AM  The Real Reason Big Pharma Wants to Help Pay for Your Prescription at Bloomberg
May-18-16 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences PR Newswire
May-17-16 03:07PM  Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q1, 2016 By the Numbers
03:02PM  5 Top Biotech Stocks to Buy on Sale at Motley Fool
May-16-16 01:00PM  Mariner Investments Top Healthcare Picks at Insider Monkey
May-11-16 11:52AM  Jazz Pharma Rises As Competitive Position Grows Stronger
11:52AM  Jazz Pharma Rises As Competitive Position Grows Stronger at Investor's Business Daily
08:10AM  Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
03:31AM  Edited Transcript of JAZZ earnings conference call or presentation 10-May-16 8:30pm GMT
May-10-16 06:30PM  Jazz Pharmaceuticals (JAZZ) Posts Q1 Earnings Beat, Updates 2016 Outlook
05:16PM  Jazz misses Street 1Q forecasts AP
04:50PM  After-Hours Earnings: Disney Misses, EA Tops, Fossil Crumbles at Investor's Business Daily
04:32PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
04:05PM  Jazz Pharmaceuticals Announces First Quarter 2016 Financial Results PR Newswire
07:07AM  Q1 2016 Jazz Pharmaceuticals PLC Earnings Release - After Market Close CCBN
May-09-16 10:13AM  Drug Stocks Reporting on May 10: XON, ARIA, CPRX & More Zacks
08:33AM  Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season? Zacks
May-06-16 05:13PM  Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock? Zacks
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, a late-stage investigational compound, which is in phase III clinical trail for the treatment of EDS in narcolepsy and obstructive sleep apnea; and JZP-386, a deuterium-modified analog of sodium oxybate that is completed phase I clinical trail for use in patients with narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLER MICHAEL PATRICKSVP, US CommercialJul 15Sale142.4310014,24317,625Jul 18 07:55 PM
Smith Karen L.Global Head of R&D and CMOJul 13Buy143.6358083,30513,574Jul 13 08:09 PM
MILLER MICHAEL PATRICKSVP, US CommercialJun 15Sale149.6410014,96417,725Jun 16 05:33 PM
Smith Karen L.Global Head of R&D and CMOJun 13Buy149.6155783,33512,994Jun 15 05:17 PM
Mulligan SeamusDirectorMay 24Sale150.2927,9684,203,3391,074,611May 26 05:02 PM
MILLER MICHAEL PATRICKSVP, US CommercialMay 16Sale145.2010014,52017,753May 17 05:56 PM
RIEDEL NORBERT GDirectorMay 16Sale145.2064493,5094,221May 17 05:39 PM
McSharry Heather AnnDirectorMay 16Sale145.20697101,2045,396May 17 05:31 PM
WILSON KAREN JSVP, Finance & PAOApr 25Sale160.0060496,64018,059Apr 27 06:15 PM
MILLER MICHAEL PATRICKSVP, US CommercialApr 15Sale145.7910014,57918,792Apr 18 05:04 PM
Cox Russell J.EVP & COOApr 12Sale136.984,000547,92060,470Apr 13 04:29 PM
WILSON KAREN JSVP, Finance & PAOApr 07Sale140.902,161304,48523,670Apr 08 04:43 PM
MILLER MICHAEL PATRICKSVP, US CommercialMar 15Sale129.1710012,91718,892Mar 16 05:48 PM
COZADD BRUCE CChairman & CEOMar 08Sale126.042,500315,100300,066Mar 09 07:26 PM
Treacy PaulSVP, Technical OperationsFeb 29Sale123.4835443,71215,100Mar 02 05:59 PM
Mulligan SeamusDirectorFeb 23Sale122.7127,9683,431,9041,102,579Feb 24 07:56 PM
COZADD BRUCE CChairman & CEOFeb 09Sale111.372,500278,425281,896Feb 11 05:01 PM
MILLER MICHAEL PATRICKSVP, US CommercialJan 15Sale122.6610012,26613,561Jan 21 11:43 AM
COZADD BRUCE CChairman & CEOJan 12Sale123.812,500309,525284,396Jan 14 06:52 PM
ENRIGHT PATRICK GDirectorJan 05Sale138.0910,0001,380,8904,519Jan 07 04:46 PM
MILLER MICHAEL PATRICKSVP, US CommercialDec 15Sale136.9910013,69913,661Dec 17 04:11 PM
ENRIGHT PATRICK GDirectorDec 02Sale148.4942462,9601,310Dec 03 04:29 PM
ENRIGHT PATRICK GDirectorDec 01Sale146.5910,0001,465,9104,716Dec 03 04:29 PM
Mulligan SeamusDirectorNov 23Sale147.9010,2431,514,9281,130,547Nov 24 06:50 PM
Mulligan SeamusDirectorNov 20Sale144.6817,7252,564,3681,140,790Nov 24 06:50 PM
MILLER MICHAEL PATRICKSVP, US CommercialNov 16Sale134.0310013,40313,690Nov 17 08:47 PM
McGill IainSVP, Europe & Rest of WorldNov 13Sale135.672,821382,73719,146Nov 17 05:24 PM
COZADD BRUCE CChairman & CEONov 10Sale128.532,500321,325289,355Nov 12 07:19 PM
ENRIGHT PATRICK GDirectorNov 10Sale135.2910,0001,352,8624,912Nov 12 04:25 PM
COZADD BRUCE CChairman and CEOOct 13Sale131.502,500328,750291,855Oct 15 04:04 PM
ENRIGHT PATRICK GDirectorOct 05Sale133.7910,0001,337,8605,108Oct 07 04:13 PM
MILLER MICHAEL PATRICKSVP, US CommercialSep 25Sale145.2310014,52313,890Sep 29 06:56 PM
COZADD BRUCE CChairman and CEOSep 08Sale163.072,500407,679294,355Sep 09 07:14 PM
ENRIGHT PATRICK GDirectorSep 01Sale165.9910,0001,659,8525,304Sep 03 04:03 PM
ENRIGHT PATRICK GDirectorAug 27Sale167.8742571,3451,734Aug 31 04:06 PM
COZADD BRUCE CChairman and CEOAug 11Sale177.822,500444,550296,855Aug 12 05:35 PM
Hooper Suzanne SawochkaEVP and General CounselAug 11Sale177.824,000711,28037,855Aug 12 05:33 PM
Cox Russell J.EVP & Chief Commercial OfficerAug 11Sale177.8250088,91058,602Aug 12 05:31 PM
Sohn Catherine A.DirectorAug 11Sale177.82654116,2935,384Aug 11 05:44 PM
Treacy PaulSVP, Technical OperationsAug 11Sale177.821,330236,49411,401Aug 11 05:54 PM
Winningham Rick EDirectorAug 10Sale180.00801144,17814,659Aug 11 05:46 PM
Sohn Catherine A.DirectorAug 10Sale180.00801144,1806,038Aug 11 05:44 PM
RIEDEL NORBERT GDirectorAug 10Sale180.00801144,1784,865Aug 11 05:41 PM
McSharry Heather AnnDirectorAug 10Sale179.99867156,0526,093Aug 11 05:37 PM
Gray PeterDirectorAug 10Sale180.00867156,0595,389Aug 11 05:35 PM
ENRIGHT PATRICK GDirectorAug 10Sale182.0210,0001,820,1775,500Aug 11 05:34 PM
ENRIGHT PATRICK GDirectorAug 10Sale180.00801144,1782,159Aug 11 05:34 PM
BERNS PAUL LDirectorAug 10Sale180.00801144,1785,589Aug 11 05:32 PM